Breaking News Instant updates and real-time market news.

EXC

Exelon

09:34
07/17/17
07/17
09:34
07/17/17
09:34

Exelon upgraded to Outperform from Peer Perform at Wolfe Research

  • 02

    Aug

EXC Exelon

07/17/17
DBAB
07/17/17
NO CHANGE
Target $41
DBAB
Buy
Exelon scored big legal win on Friday, says Deutsche Bank
Deutsche Bank analyst Jonathan Arnold says he learned Friday that the judge in the challenge brought against the Illinois Zero Emission Credit program had ruled categorically in favor of Exelon's motion to dismiss the case. The decision, while unlikely to be the final word, looks like an "important and comprehensive first win" for Exelon in a case with direct implications for $235M of annual revenues, Arnold tells investors in a research note. He has a Buy rating on the shares with a $41 price target.
06/14/17
RHCO
06/14/17
NO CHANGE
RHCO
Exelon merchant assets 'significantly undervalued,' says SunTrust
After meeting with Exelon's CFO, SunTrust analyst Ali Agha says that the company's merchant assets are significantly undervalued. He expects the company, within 18 months, to either use a portion of the unit's free cash flow to buy back shares or sell a stake in the business. The analyst raised his price target on the stock to $40 from $39 and keeps a Buy rating on the shares.
05/24/17
FBCO
05/24/17
NO CHANGE
FBCO
Outperform
Exelon a net winner despite 'disappointing' 2020/21 auction, says Credit Suisse
Following PJM Interconnection's annual capacity auction, Credit Suisse analyst Michael Weinstein called Exelon a net winner despite "disappointing" RPM results for the 2020/21 capacity auction. The results for the EMAAC area should help drive a net positive result for Exelon assuming the same amount of capacity cleared year-over-year, he indicated. PSEG (PEG) and Calpine (CPN)are also "net beneficiaries," while Dynegy (DYN), NRG Energy (NRG) and FirstEnergy (FE) will "bear the brunt of a poor RTO showing," Weinstein tells investors.
05/15/17
UBSW
05/15/17
UPGRADE
Target $38
UBSW
Buy
Exelon upgraded to Buy from Neutral at UBS
UBS analyst Julien Dumoulin-Smith upgraded Exelon to Buy from Neutral citing its relative underperformance and its current valuation, which the analysts feels "is too cheap to ignore". The analyst feels the shares have been held back by investors concerns surrounding the PJM capacity auction and the ZEC legislation in New York and Illinois. Dumoulin-Smith feels those concerns are priced in already and raised his price target to $37.50 from $36 on Exelon shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.